NRX Pharmaceuticals Inc Ordinary Shares NRXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
Trading Information
- Previous Close Price
- $2.44
- Day Range
- $2.25–2.44
- 52-Week Range
- $1.62–5.06
- Bid/Ask
- $2.27 / $2.30
- Shares Outstanding
- 43.30M
- Market Cap
- $98.71M
- Volume/Avg
- 598,884 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 29
- Website
- https://nrxpharma.com
Valuation
Metric | NRXP |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 21.77 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NRXP |
|---|---|
Quick Ratio | 0.79 |
Current Ratio | 0.86 |
Interest Coverage | −19.59 |
Quick Ratio
NRXP
Profitability
Metric | NRXP |
|---|---|
Return on Assets (Normalized) | −92.69% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NRXP
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|G%!c>@ | LOCK|K<%> | $139B | |||
| Moderna Inc MRNA | LOCK|p&$@!!l | LOCK|xc | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|xT<S<B | LOCK|&#$Ln | $99B | |||
| argenx SE ADR ARGX | LOCK|m%>&qzq | LOCK|b% | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|LYzQ^Y | LOCK|?Qj | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|t&?wtV>H | LOCK|qb^!m | $31B | |||
| Incyte Corp INCY | LOCK|X>h^DW | LOCK|h?f | $25B | |||
| BioNTech SE ADR BNTX | LOCK|!bVpGYr | LOCK|T! | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$sx!GSX | LOCK|@SLJ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|t%hlD$d | LOCK|%S | $16B |
United States